Literature DB >> 15353579

Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells.

Roland Schoop1, Patricia Wahl, Michel Le Hir, Uwe Heemann, Minghui Wang, Rudolf P Wüthrich.   

Abstract

BACKGROUND: The interaction of the T-cell molecule PD-1 (programmed death-1) with its ligands PD-L1 and PD-L2 represents a known mechanism of T-cell inhibition. PD-1 is homologous to CD28 while the PD-1 ligands share homology with the B7 family of co-stimulatory molecules.
METHODS: We have studied surface expression and transcript levels of PD-L1 and PD-L2 on murine renal tubular epithelial cells (TEC) by flow cytometric analysis and reverse transcription-polymerase chain reaction. Western blot analysis was used to confirm protein expression of PD-L1. We also tested the functional role of PD-L1 and PD-1 in antigen presentation. Furthermore, we stained mouse kidney transplants with rejection for the expression of the PD-1 ligands.
RESULTS: We found that PD-L1 but not PD-L2 was weakly expressed on unstimulated TEC. Upon stimulation with IFN-gamma, a dose-dependent upregulation of PD-L1 expression was observed. Blockade of the PD-L1/PD-1 pathway with monoclonal antibodies in antigen presentation assays uncovered an inhibitory role of this ligand system in Th1 and Th2 cell activation. Staining for PD-L1 was strong in proximal and distal tubules in mouse kidney transplants with rejection, whereas staining of normal kidneys and syngenic mouse kidney transplants did not reveal PD-L1 expression. PD-L2 was not observed in normal or rejected mouse kidneys.
CONCLUSIONS: These data demonstrate that PD-L1 is an inducible renal tubular epithelial antigen that negatively regulates T-cell responses elicited by IFN-gamma-stimulated TEC. We speculate that the PD-1/PD-L1 pathway may play a role in protecting the epithelium from immune-mediated tubulointerstitial injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353579     DOI: 10.1093/ndt/gfh423

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  36 in total

Review 1.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

2.  Airway epithelial cells suppress T cell proliferation by an IFNγ/STAT1/TGFβ-dependent mechanism.

Authors:  Christine M Deppong; Jian Xu; Steven L Brody; Jonathan M Green
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

3.  Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis.

Authors:  Bechara Mfarrej; Mary Keir; Shirine Dada; Subbulaxmi Trikudanathan; Mohamed H Sayegh; Arlene H Sharpe; Indira Guleria
Journal:  Clin Immunol       Date:  2011-03-24       Impact factor: 3.969

Review 4.  FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance.

Authors:  Alessandro Alessandrini; Laurence A Turka
Journal:  Am J Kidney Dis       Date:  2016-12-31       Impact factor: 8.860

5.  Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma.

Authors:  M L Madariaga; S G Michel; G M La Muraglia; M Sekijima; V Villani; D A Leonard; H J Powell; J M Kurtz; E A Farkash; R B Colvin; J S Allan; C L Cetrulo; C A Huang; D H Sachs; K Yamada; J C Madsen
Journal:  Am J Transplant       Date:  2015-03-30       Impact factor: 8.086

6.  End-organ damage in a mouse model of fulminant liver inflammation requires CD4+ T cell production of IFN-gamma but is independent of Fas.

Authors:  Richard T Robinson; Jing Wang; James G Cripps; Michael W Milks; Kathryn A English; Todd A Pearson; James D Gorham
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy.

Authors:  M Xipell; I Victoria; V Hoffmann; J Villarreal; A García-Herrera; O Reig; L Rodas; M Blasco; E Poch; B Mellado; L F Quintana
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

8.  Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.

Authors:  Tyce J Kearl; Weiqing Jing; Jill A Gershan; Bryon D Johnson
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

9.  PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.

Authors:  Bettina Schreiner; Samantha L Bailey; Tahiro Shin; Lieping Chen; Stephen D Miller
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

10.  Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.

Authors:  Ming-Fei Liu; Chia-Tse Weng; Meng-Yu Weng
Journal:  J Biomed Biotechnol       Date:  2009-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.